Short and Long-term Clinical Efficacy of Montelukast Sodium in the Treatment of Cough Variant Asthma and the Effect on Serum Inflammatory Factors in Children
CHEN Xiujin, et al
Jianyang Maternal and Child Health Care Center,Sichuan Jianyang 641400, China
Abstract：Objective: To investigate the short and long- term clinical efficacy of montelukast sodium in the treatment of cough variant asthma and the effects on serum levels of tumor necrosis factor -α (TNF-α), interleukin-8 (IL-8), interleukin-10 (IL-10), and immune globulin E (IgE) in children. Methods: Totally 80 eligible children were selected, and randomly divided into observation group and control group, with 40 children in each group. Both groups were given conventional therapies, and beclometasone dipropionate inhalation aerosol was used additionally to the control group, while montelukast sodium chewable tablets was used additionally to the observation group, both used successively for 3 months. The clinical efficacy was assessed, and the serum levels of TNF-α, IL-8, IL-10, and IgE were determined before and after treatment. Results: In the observation group, 21 children were clinically controlled, of which 9 were responsive to the therapy excellently, 7 were responsive to the therapy, and 3 were unresponsive to the therapy,so the overall response rate was 75.00%; while in the control group, 13 children were clinically controlled, of which 8 were responsive to the therapy excellently, 13 were responsive to the therapy, and 6 were unresponsive to the therapy, so the overall response rate was 52.50%. The differences were statistically significant (P<0.05). The disappearance time of common symptoms such as cough, angina, and itching throat in the observation group were significantly shorter than those in the control group (P<0.05). Before the treatment, the serum level of TNF-α, IL-8, IL-10, and IgE were similar in two groups, the difference was statistically insignificant (P >0.05); After treatment, the serum level of TNF-α, IL-8, IL-10, and IgE were significantly improved in both groups compared with those before treatment, while the improving extents in the observation group were greater than those in the control group, the difference was statistically significant (P<0.05). 1 year after the treatment, totally 7 children of the observation group experienced relapse and the relapse rate was 17.50%; while totally 14 children experienced relapse and the relapse rate was 35.00%; and the difference was statistically significant (P<0.05). Conclusion: In the treatment of cough variant asthma in children, Montelukast sodium has good short-term clinical efficacy, and can shorten the symptomatic improvement time, lighten the inflammatory reactions, and reduce the long-term relapse rate.
陈秀锦, 李丽华. 孟鲁司特钠治疗咳嗽变异性哮喘患儿的近远期临床效果及对血清炎性因子的影响[J]. 河北医学, 2017, 23(2): 208-211.
CHEN Xiujin, et al. Short and Long-term Clinical Efficacy of Montelukast Sodium in the Treatment of Cough Variant Asthma and the Effect on Serum Inflammatory Factors in Children. HeBei Med, 2017, 23(2): 208-211.
2017, Vol. 23 
冀公网安备13080202000677号